TP53 and B-cell chronic lymphocytic leukemia: In CLL, drug sensitivity is affected not only by intrinsic features of the leukemic cells, such as the presence of TP53 abnormalities and UM IGHV status, but also by the interactions of neoplastic cells with the surrounding microenvironment26,31–33.